Phage therapy: Awareness and demand among clinicians in the United Kingdom.
Bacterial resistance or tolerance to antibiotics is costly to patients and healthcare providers. With the impact of antibiotic resistance forecast to grow, alternative antimicrobial approaches are needed to help treat patients with antibiotic refractory infections and reduce reliance upon existing a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0294190&type=printable |
| _version_ | 1797249200996483072 |
|---|---|
| author | Emily A Simpson Helen J Stacey Ross J Langley Joshua D Jones |
| author_facet | Emily A Simpson Helen J Stacey Ross J Langley Joshua D Jones |
| author_sort | Emily A Simpson |
| collection | DOAJ |
| description | Bacterial resistance or tolerance to antibiotics is costly to patients and healthcare providers. With the impact of antibiotic resistance forecast to grow, alternative antimicrobial approaches are needed to help treat patients with antibiotic refractory infections and reduce reliance upon existing antibiotics. There is renewed interest in bacteriophage (phage) therapy as a promising antimicrobial strategy. We therefore performed the first multi-specialty survey about phage therapy and the first such survey among clinicians in the United Kingdom. An anonymous 10-question survey of clinicians from medical and surgical specialties in two Scottish Health Boards was performed. The 90 respondents spanned 26 specialties and were predominantly consultants (73.3%). The respondents were concerned about antibiotic resistance in their clinical practice; 83 respondents estimated having seen 711 patients in the last 12 months whose infections were refractory to antibiotics (delaying or preventing resolution). Over half (58.8%) of the respondents had previously heard of phage therapy. Staphylococci, Pseudomonas and E. coli were identified as the highest cross-specialty priorities for the development of phage therapy. Together, 77 respondents estimated seeing 300 patients in the last 12 months for whom phage therapy may have been appropriate (an average of 3.9 patients per clinician). Most respondents (71.1%, n = 90) were already willing to consider using phage therapy in appropriate cases. Additional comments from the respondents affirmed the potential utility of phage therapy and highlighted a need for more information. The results of this survey demonstrate substantial demand for and willingness to use phage therapy in appropriate cases, both from individual clinicians and across specialties. Demand from a wide range of specialties illustrates the broad clinical utility of phage therapy and potential scope of impact. Widening access to phage therapy could deliver substantial clinical and financial benefits for patients and health authorities alike. |
| first_indexed | 2024-03-09T00:21:07Z |
| format | Article |
| id | doaj.art-39ac1e1773dd436593c85845234b8366 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-24T20:26:43Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-39ac1e1773dd436593c85845234b83662024-03-22T05:35:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-011811e029419010.1371/journal.pone.0294190Phage therapy: Awareness and demand among clinicians in the United Kingdom.Emily A SimpsonHelen J StaceyRoss J LangleyJoshua D JonesBacterial resistance or tolerance to antibiotics is costly to patients and healthcare providers. With the impact of antibiotic resistance forecast to grow, alternative antimicrobial approaches are needed to help treat patients with antibiotic refractory infections and reduce reliance upon existing antibiotics. There is renewed interest in bacteriophage (phage) therapy as a promising antimicrobial strategy. We therefore performed the first multi-specialty survey about phage therapy and the first such survey among clinicians in the United Kingdom. An anonymous 10-question survey of clinicians from medical and surgical specialties in two Scottish Health Boards was performed. The 90 respondents spanned 26 specialties and were predominantly consultants (73.3%). The respondents were concerned about antibiotic resistance in their clinical practice; 83 respondents estimated having seen 711 patients in the last 12 months whose infections were refractory to antibiotics (delaying or preventing resolution). Over half (58.8%) of the respondents had previously heard of phage therapy. Staphylococci, Pseudomonas and E. coli were identified as the highest cross-specialty priorities for the development of phage therapy. Together, 77 respondents estimated seeing 300 patients in the last 12 months for whom phage therapy may have been appropriate (an average of 3.9 patients per clinician). Most respondents (71.1%, n = 90) were already willing to consider using phage therapy in appropriate cases. Additional comments from the respondents affirmed the potential utility of phage therapy and highlighted a need for more information. The results of this survey demonstrate substantial demand for and willingness to use phage therapy in appropriate cases, both from individual clinicians and across specialties. Demand from a wide range of specialties illustrates the broad clinical utility of phage therapy and potential scope of impact. Widening access to phage therapy could deliver substantial clinical and financial benefits for patients and health authorities alike.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0294190&type=printable |
| spellingShingle | Emily A Simpson Helen J Stacey Ross J Langley Joshua D Jones Phage therapy: Awareness and demand among clinicians in the United Kingdom. PLoS ONE |
| title | Phage therapy: Awareness and demand among clinicians in the United Kingdom. |
| title_full | Phage therapy: Awareness and demand among clinicians in the United Kingdom. |
| title_fullStr | Phage therapy: Awareness and demand among clinicians in the United Kingdom. |
| title_full_unstemmed | Phage therapy: Awareness and demand among clinicians in the United Kingdom. |
| title_short | Phage therapy: Awareness and demand among clinicians in the United Kingdom. |
| title_sort | phage therapy awareness and demand among clinicians in the united kingdom |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0294190&type=printable |
| work_keys_str_mv | AT emilyasimpson phagetherapyawarenessanddemandamongcliniciansintheunitedkingdom AT helenjstacey phagetherapyawarenessanddemandamongcliniciansintheunitedkingdom AT rossjlangley phagetherapyawarenessanddemandamongcliniciansintheunitedkingdom AT joshuadjones phagetherapyawarenessanddemandamongcliniciansintheunitedkingdom |